CClinicalTrials.gg
Status unknownNCT04615806Updated Jan 25, 2022

The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy

An interventional study of Indocyanine green solution in Esophageal Cancer and Indocyanine Green, sponsored by Fujian Medical University Union Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-25.

Sponsored by Fujian Medical University Union Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Indocyanine green (ICG) has been recently introduced in clinical practice as a fuorescent tracer. Lymphadenectomy is particularly challenging in esophageal cancer surgery, owing to the complex anatomical drainage.Therefore, the purpose of this study was to explore whether the NIR-ICG imaging system could accurately assess the lymph node markers during radical resection of esophageal cancer.

Read the detailed description

This study will be accepted in esophageal cancer patients with Radical Esophag-ectomy as the research object.We will divide them into two groups: experimental group for injection of indocyanine green group and control group for injectable in-docyanine green group.We will compare with the accuracy,false positive rate and false negative rate,sensitivity, specificity and related indicators of intraoperative lymph node cleaning,in order to explore the common position of esophageal cancer sentinel lymph node,guidance of esophageal cancer lymph node cleaning thoroughly.

02

Conditions studied

  • Esophageal Cancer
  • Indocyanine Green

Keywords

  • Esophageal Cancer
  • Indocyanine Green
  • the lymph node markers
03

In context

Esophageal Neoplasms

1,593 studies on the registry are indexed under Esophageal Neoplasms; 461 are open to participants now.

This study's planned enrollment of 40 is below the median of 58 across 1,171 interventional studies indexed under Esophageal Neoplasms.

Browse Esophageal Neoplasms studies →

Lead sponsor

Fujian Medical University Union Hospital is the lead sponsor of 100 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age and gender: 18-75 years old, male and female unlimited;
  2. Preoperative biopsy was pathologically diagnosed as esophageal squamous cell carcinoma;
  3. Preoperative combination with neoadjuvant chemoradiotherapy;
  4. Surgical resection of esophageal carcinoma under endoscopic selection and intraoperative anastomosis;
  5. Heart, lung, liver and kidney functions can tolerate operation;
  6. Patients and their family members can understand and are willing to participate in this clinical study and sign the informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Allergic to ICG or iodine;
  2. Patients with a history of chest surgery or thoracic lymph node dissection;
  3. Patients needing emergency surgery;
  4. Patients whose tumors involve neighboring organs and need to be removed by combining organs;
  5. Patients with tumor recurrence or distant metastasis;
  6. Patients who had participated in or were participating in other clinical trials within the previous 4 weeks were included;
  7. A history of serious mental illness;
  8. Pregnant or lactating women;
  9. Patients with other conditions considered by the researcher should not participate in the study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    NIR-ICG

    After positioning,Indocyanine green(ICG) dye (Yichuang Pharmaceutical, Liaoning, China) stored at a dose of 25 mg in a small bottle was diluted with 5 ml sterile water. Then, 2 ml of this solution was added to 8 ml sterile water in a dis-posable dressing bowl, resulting in a final concentration of 1.25 mg/ml.

    Drug: Indocyanine green solution

  • No intervention
    Control

    This group of patients received only conventional radical resection of esophageal cancer without Indocyanine green injection.

Interventions

  • DrugIndocyanine green solution

    ICG solution was endoscopically injected into the esophageal submucosa at the four quadrants around the tumor.

    Also known as: Indocyanine Green for Injection

06

What researchers measure

Primary outcomes

  1. Accuracy rate of lymph node dissection

    Accuracy rate of lymph node dissection of each arm(according to postoperative pathology)

    Time frame: 1 week after operation

  2. False positive rate of lymph node dissection

    False positive rate of lymph node dissectionof each arm(according to postoperative pathology)

    Time frame: 1 week after operation

  3. False negative rate of lymph node dissection

    False negative rate of lymph node dissection of each arm(according to postoperative pathology)

    Time frame: 1 week after operation

  4. Sensitivity and specificity of lymph node dissection

    Sensitivity and specificity of lymph node dissection of each arm(according to postoperative pathology)

    Time frame: 1 week after operation

Secondary outcomes

  1. The mapping of sentinel lymph nodes in esophageal cancer

    The mapping of sentinel lymph nodes in esophageal cancer

    Time frame: 1 week after operation

07

Study locations

1 of 1 sites recruiting
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
    Recruiting
08

References and documents

Publications

  • Du J, Xu G, Yang Z, Zheng B, Chen C. Pericancerous lymph node imaging with indocyanine green-guided near-infrared fluorescence in radical esophagectomy: Protocol for a single-center, prospective, randomized controlled clinical trial. Thorac Cancer. 2022 Aug;13(15):2283-2287. doi: 10.1111/1759-7714.14548. Epub 2022 Jun 29. PubMed 35770339 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04615806
Lead sponsor
Fujian Medical University Union Hospital
Responsible party
Sponsor
First posted
Nov 4, 2020
Start date
Sep 22, 2020
Primary completion
Sep 30, 2022 (estimated)
Completion
Sep 30, 2023 (estimated)
Last update
Jan 25, 2022

Study contacts

Bin Zheng, MD
Contact
Dujt1220@qq.com
13023806690
Chun Chen, MD
study director · Fujian Medical University Union Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion